What medicine is Rucaparib?

Rucaparib, sold under the brand nameRubraca, is a PARP inhibitor used as an anticancer agent. Rucapanib is the first drug of its kind that targets the DNA repair enzyme poly-ADP ribose polymerase-1 (PARP-1) and is administered orally. The most common side effects include fatigue or weakness, nausea, increased blood creatinine levels and liver enzyme levels, vomiting, anemia, decreased appetite, dysgeusia, diarrhea, thrombocytopenia, and abdominal pain.

Rucaparib is indicated for the maintenance treatment of adult patients with BRCA mutation (germline and/or somatic)-associated recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who have a complete or partial response to platinum-based chemotherapy Rucaparib is also currently indicated for the treatment of adult patients with deleterious BRCA mutation (germline and/or somatic)-associated metastatic castration-resistant prostate cancer who have received androgen receptor-directed therapy and taxane-based chemotherapy.

The original drug Rucapani has not yet been marketed in the country, so it has not entered the medical insurance coverage standards. The European version of rucapani original drug, specifications300mg*60 tablets sold overseas may cost more than 20,000 yuan per box (the price may fluctuate due to exchange rate effects), which is relatively expensive. There are also cheap generic rucapani drugs available overseas, and their pharmaceutical ingredients are basically the same as those of the original rucapani drug. For example, in India, the price of BDR pharmaceutical specifications of 300mg*60 tablets per box may be more than 6,000 yuan (the price may fluctuate due to exchange rate effects).